Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic biomarkers associated with risk of developing severe drug eruptions and clinical implementation of HLA genetic testing

6 Apr 2025

Abstract excerpt

The association of human leukocyte antigen (HLA) with the risk of drug-induced skin eruptions has been extensively studied. The sensitivity of the association of specific HLA alleles with drug eruptions ranges from approximately 50 to 100%, indicating a significant influence of HLA alleles on the risk of developing such reactions. Consequently, HLA testing holds substantial clinical potential as a genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Bullous Skin Diseases
Share to Drug-Induced Adverse Reactions
Share to Immunodeficiency and Autoimmune Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40187963
DOI: 10.1016/j.alit.2025.03.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic biomarkers associated with risk of developing severe drug eruptions and clinical implementation of HLA genetic testingPMID 40187963Read ↗

Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art.Semantic proximity Read ↗

Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation.Semantic proximity Read ↗

HLA-B Genotyping to Detect Carbamazepine-Induced Stevens-Johnson Syndrome: Implications for Personalizing MedicineSemantic proximity Read ↗

Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.Semantic proximity Read ↗

Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse ReactionsSemantic proximity Read ↗

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

An update on HLA alleles associated with adverse drug reactions.Semantic proximity Read ↗

A Recent Update of Pharmacogenomics in Drug-induced Severe Skin ReactionsSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdateSemantic proximity Read ↗

Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.Semantic proximity Read ↗

The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactionsSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.